Danazol is a generic version of Danocrine marketed by Sanofi-Aventis. It represses a sex hormone called gonadotropin, and is indicated for the treatment of uterine tissue growing outside of the uterus.
According to NDC Health, total sales of generic Danazol capsules were $16 million in 2004.
“Our efforts to develop a more robust pipeline are beginning to bear fruit,” said Arthur Bedrosian, president of Lannett. “The approval of Danazol capsules combined with recent product launches adds important new drugs to our product offering. In addition, with a number of drug applications now pending at the FDA, we expect to receive more drug approvals in the coming months.”